CCCC vs. ALEC, INBX, KURA, AVDL, KNSA, NRIX, DAWN, ANIP, RCUS, and GYRE
Should you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Alector (ALEC), Inhibrx (INBX), Kura Oncology (KURA), Avadel Pharmaceuticals (AVDL), Kiniksa Pharmaceuticals (KNSA), Nurix Therapeutics (NRIX), Day One Biopharmaceuticals (DAWN), ANI Pharmaceuticals (ANIP), Arcus Biosciences (RCUS), and Gyre Therapeutics (GYRE). These companies are all part of the "medical" sector.
C4 Therapeutics (NASDAQ:CCCC) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, community ranking, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.
Alector has a net margin of -125.11% compared to C4 Therapeutics' net margin of -629.24%. C4 Therapeutics' return on equity of -52.85% beat Alector's return on equity.
C4 Therapeutics presently has a consensus target price of $8.71, suggesting a potential upside of 34.07%. Alector has a consensus target price of $14.00, suggesting a potential upside of 115.72%. Given Alector's stronger consensus rating and higher possible upside, analysts clearly believe Alector is more favorable than C4 Therapeutics.
78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 8.0% of C4 Therapeutics shares are owned by company insiders. Comparatively, 9.1% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
C4 Therapeutics has a beta of 3.07, indicating that its share price is 207% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.
In the previous week, C4 Therapeutics had 1 more articles in the media than Alector. MarketBeat recorded 6 mentions for C4 Therapeutics and 5 mentions for Alector. Alector's average media sentiment score of 0.80 beat C4 Therapeutics' score of 0.27 indicating that Alector is being referred to more favorably in the news media.
Alector has higher revenue and earnings than C4 Therapeutics. Alector is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.
Alector received 123 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 60.91% of users gave Alector an outperform vote while only 37.88% of users gave C4 Therapeutics an outperform vote.
Summary
Alector beats C4 Therapeutics on 13 of the 18 factors compared between the two stocks.
Get C4 Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
C4 Therapeutics Competitors List
Related Companies and Tools
